Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLNNNASDAQ:LNSRNASDAQ:PASGNASDAQ:SYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLNNClene$3.00+16.3%$4.31$2.57▼$9.20$25.76M0.2778,638 shs57,049 shsLNSRLENSAR$14.10+0.3%$12.39$2.67▼$17.31$166.23M0.6262,830 shs179,835 shsPASGPassage Bio$0.39+1.3%$0.50$0.32▼$1.64$24.30M1.55329,141 shs44,622 shsSYRASyra Health$0.18-34.0%$0.39$0.13▼$2.27$2.01M3.2774,492 shs3.66 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLNNClene+16.28%-15.25%-30.72%-44.34%-62.12%LNSRLENSAR+0.28%-0.28%+4.60%+62.26%+309.88%PASGPassage Bio+1.30%-15.02%-18.54%-52.89%-69.92%SYRASyra Health-34.05%-40.96%-53.62%-59.52%-86.52%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLNNClene3.5186 of 5 stars3.65.00.00.02.92.50.6LNSRLENSAR0.6096 of 5 stars1.03.00.00.01.42.50.0PASGPassage Bio2.8567 of 5 stars3.54.00.00.01.11.71.3SYRASyra Health0.8973 of 5 stars0.04.00.00.02.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLNNClene 3.20Buy$55.251,741.67% UpsideLNSRLENSAR 2.00Hold$15.006.38% UpsidePASGPassage Bio 3.00Buy$7.501,818.16% UpsideSYRASyra Health 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SYRA, CLNN, LNSR, and PASG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/24/2025CLNNCleneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.003/24/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.003/24/2025LNSRLENSARBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/24/2025LNSRLENSARLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$16.00 ➝ $15.003/12/2025CLNNCleneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.003/12/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.003/4/2025PASGPassage BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $6.002/28/2025LNSRLENSARLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $16.002/25/2025CLNNCleneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.002/25/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.002/6/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLNNClene$342K75.32N/AN/A$2.09 per share1.44LNSRLENSAR$53.49M3.11N/AN/A$2.97 per share4.75PASGPassage BioN/AN/AN/AN/A$2.03 per shareN/ASYRASyra Health$7.98M0.25N/AN/A$0.62 per share0.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLNNClene-$49.50M-$5.75N/AN/AN/A-8,556.77%-1,106.30%-85.11%5/6/2025 (Estimated)LNSRLENSAR-$14.38M-$2.72N/A∞N/A-34.03%-49.02%-21.12%5/7/2025 (Estimated)PASGPassage Bio-$102.06M-$1.07N/AN/AN/AN/A-72.53%-52.10%5/13/2025 (Estimated)SYRASyra Health-$2.94M-$0.54N/A∞N/A-54.90%-131.94%-99.19%5/7/2025 (Estimated)Latest SYRA, CLNN, LNSR, and PASG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/24/2025Q4 2024CLNNClene-$1.21-$1.67-$0.46-$1.67$0.13 million$0.09 million3/11/2025Q4 2024SYRASyra HealthN/A-$0.05N/A-$0.05$2.01 million$2.00 million3/4/2025Q4 2024PASGPassage Bio-$0.21-$0.20+$0.01-$0.20N/AN/A2/27/2025Q4 2024LNSRLENSAR-$0.21-$1.61-$1.40-$1.61$14.95 million$16.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLNNCleneN/AN/AN/AN/AN/ALNSRLENSARN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/ASYRASyra HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLNNCleneN/A0.830.82LNSRLENSARN/A3.372.10PASGPassage BioN/A5.155.15SYRASyra HealthN/A4.634.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLNNClene23.28%LNSRLENSAR40.15%PASGPassage Bio53.48%SYRASyra Health4.75%Insider OwnershipCompanyInsider OwnershipCLNNClene25.10%LNSRLENSAR38.52%PASGPassage Bio4.30%SYRASyra Health10.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLNNClene1008.59 million6.24 millionOptionableLNSRLENSAR11011.79 million7.14 millionOptionablePASGPassage Bio13062.15 million59.11 millionOptionableSYRASyra Health7811.31 million10.16 millionNot OptionableSYRA, CLNN, LNSR, and PASG HeadlinesRecent News About These CompaniesSyria Is Trying to Get Up With a Boot on Its NeckApril 3 at 4:46 AM | nytimes.comSyra Health Corp trading halted, news pendingApril 2 at 6:44 PM | markets.businessinsider.comHow inclusive is Syria's new technocratic cabinet?April 2 at 3:42 AM | msn.comIndiana doctor seeks pacemakers as he embarks on mission to SyriaApril 2 at 3:42 AM | msn.comSyra Health Corp trading resumesApril 2 at 3:42 AM | markets.businessinsider.comSyra Health announces voluntarily delisting from NASDAQApril 2 at 3:42 AM | markets.businessinsider.comCarmel-based health tech firm to delist from NasdaqApril 2 at 3:42 AM | ibj.comSyra Health Announces Voluntary Delisting from the Nasdaq Capital MarketApril 1 at 5:00 PM | prnewswire.comSyria's president al-Sharaa forms new transitional governmentApril 1 at 2:10 AM | msn.comIs Syria's new technocratic cabinet as inclusive as it could be?March 31 at 9:08 PM | msn.comSyria’s Leader Announces New Government After Ousting DictatorMarch 30, 2025 | nytimes.comUS embassy in Syria warns of increased risk of attacks as Ramadan endsMarch 29, 2025 | msn.comFrom exile to aid: Syria's doctors returnMarch 28, 2025 | thelancet.comSyria faces severe shortage of cancer medications, official urges international aidMarch 27, 2025 | aa.com.trIsrael strikes on Syria, Lebanon 'risk further escalation': EU top diplomatMarch 24, 2025 | english.ahram.org.egLebanon and Syria agree on ceasefire after deadly cross-border clashesMarch 19, 2025 | msn.comAt least seven killed in spiralling clashes on Syria-Lebanon borderMarch 19, 2025 | msn.comSyria joins a donor conference for the first time in a crucial phase for its new leadersMarch 19, 2025 | msn.comIsrael strikes military targets in southern Syria over national security concernsMarch 18, 2025 | msn.comEU hosts donor conference to support Syria’s post-Assad transition and reconstructionMarch 17, 2025 | moneycontrol.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSYRA, CLNN, LNSR, and PASG Company DescriptionsClene NASDAQ:CLNN$3.00 +0.42 (+16.28%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$2.94 -0.06 (-1.97%) As of 04/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.LENSAR NASDAQ:LNSR$14.10 +0.04 (+0.28%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$14.12 +0.02 (+0.13%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.Passage Bio NASDAQ:PASG$0.39 +0.01 (+1.30%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$0.40 +0.01 (+1.53%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Syra Health NASDAQ:SYRA$0.18 -0.09 (-34.05%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$0.17 -0.01 (-5.62%) As of 07:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syra Health Corp., a healthcare services company, provides health education, population health management, behavioral and mental health, healthcare workforce, and digital health services in the United States. It offers health education services, including medical communications, patient education, and healthcare training; and population health management services, such as analytics as a service, epidemiology, and health equity analytics solutions. The company also engages in developing Syrenity, an on-demand telehealth platform for mental health services. In addition, the company provides healthcare staffing solutions; and digital health solutions comprising digital transformation, cloud and security, artificial intelligence, patient engagement, and health apps. It serves mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities, and pharmaceutical manufacturers. Syra Health Corp. was incorporated in 2020 and is headquartered in Carmel, Indiana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Boeing Stock Upgraded After Beating Lockheed for Jet Deal Amazon Falls Back to a Key Support Line: Here's How to Play It Why Howmet Could Be the Sleeper Aerospace Name of 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
